The Leukemia & Lymphoma Society's (LLS's) Medical and Scientific Advisory Board is comprised of leading experts in their fields. Board members volunteer their time to LLS and receive no compensation for their generous support.
The Medical and Scientific Advisory Board's role is to advise the Board of Directors on a range of issues. These include periodically reviewing LLS's medical affairs and recommending funding for research grant awards.
Subcommittees within the Advisory Board work on specific processes that relate to medical and scientific affairs.
Officers
Steven T. Rosen, MD, FACP, Chair
City of Hope
Provost, Chief Scientific Officer
Director, Comprehensive Cancer Center
Board Members
Steven Ansell, MD
Mayo Clinic, Rochester
Chair, Lymphoma Group
Leif Bergsagel, MD
Mayo Clinic, Arizona
Ravi Bhatia, MD
University of Alabama
Director, Division of Hematology & Oncology
Alan D. D'Andrea, MD
Dana-Farber Cancer Institute
Co-Director, Gene Therapy Center
Giulio Draetta, MD, PhD
MD Anderson Cancer Center
VP Operations, Strategic Research Programs
Philip Frost, MD, PhD
former Imclone, Wyeth
Irene Ghobrial, MD
Dana-Farber Cancer Institute
Co-Director, Blood Cancer Research Partnership
Catriona Jamieson, MD, PhD
The Regents of the University of California, San Diego
Stem Cell Research Program
Larry Kwak, MD
City of Hope
Director, Translational Research & Developmental Therapeutics
Michelle LeBeau, PhD
University of Chicago
Director, Comprehensive Cancer Center
Ross Levine, MD
Memorial Sloan Kettering Cancer Center
Director, MSK Center for Hematologic Malignancies
Jonathan D. Licht, MD
University of Florida
Director, Health Cancer Center
Alan F. List, MD
Moffit Cancer Center & Research Institute
EVP & President
Susan M. O'Brien, MD
Professor of Medicine
University of California/Irvine
Franklin O. Smith III, MD
Medpace
VP, Medical Affairs for Oncology Clinical Research